SCHEMBL328439

SCHEMBL328439

CN1CCC(N2CCC(c3ccc(N)cc3)CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.53
GRIN2B Q13224 3/20 0.49
QDPR P09417 2/20 0.46
ESRRB O95718 1/20 0.45
ESRRG P62508 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
TLR9 Q9NR96 4/20 0.44
TLR7 Q9NYK1 4/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
LSS P48449 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL158531 0.89 QDPR (0.55) SLC18A3QDPRHTR1DHTR1BLSS
SCHEMBL3515888 0.88 SLC18A3 (0.60) SLC18A3GRIN2BESRRBESRRGCYP2D6
SCHEMBL14320844 0.84 SLC18A3 (0.66) SLC18A3GRIN2BESRRBESRRGCYP2D6
SCHEMBL16764376 0.83 SLC18A3 (0.69) SLC18A3GRIN2BESRRBESRRGCYP2D6
Hydrochloric Acid SCHEMBL16763707 0.83 SLC18A3 (0.64) SLC18A3GRIN2BESRRBESRRGCYP2D6
Hydrochloric Acid SCHEMBL16763829 0.83 SLC18A3 (0.59) SLC18A3GRIN2BESRRBESRRGCYP2D6
SCHEMBL10127720 0.81 GRIN2B (0.48) SLC18A3GRIN2BQDPRCYP2D6CYP2C19
SCHEMBL24125741 0.80 SLC18A3 (0.53) SLC18A3GRIN2BQDPRESRRBESRRG
SCHEMBL27424037 0.80 SLC18A3 (0.49) SLC18A3GRIN2BESRRBESRRGCYP2D6
SCHEMBL14320804 0.79 SLC18A3 (0.46) SLC18A3QDPRHTR1DHTR1BLSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 SLC18A3 3875/4885GRIN2B 2683/4885QDPR 986/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 SLC18A3 3875/4885GRIN2B 2683/4885QDPR 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.